TCA‐100 tumour chemosensitivity assay: Differences in sensitivity between cultured tumour cell lines and clinical studies
- 1 November 1994
- journal article
- research article
- Published by Wiley in Journal of Bioluminescence and Chemiluminescence
- Vol. 9 (6) , 373-378
- https://doi.org/10.1002/bio.1170090604
Abstract
The BATLE LE TCA‐100 tumour chemosensitivity assay has been used to evaluate chemotherapeutic drug sensitivity of cultured tumour cell lines. Studies were performed using test drug concentrations calibrated to discriminate sensitivity and resistance of clinical specimens. Strong sensitivity which appeared to be inconsistent with clinical experience was detected for some drugs and cell lines. Findings of strong sensitivity were consistent with basic differences between sensitivity testing cultured cell lines and clinical specimens. Results with cell lines frequently may not apply directly to clinical applications. Characterization of differences between cell lines and clinical specimens may assist in application of cell line findings to clinical trials.Keywords
This publication has 6 references indexed in Scilit:
- Prediction of Response to Drug Therapy of CancerDrugs, 1992
- In vitro growth ability and chemosensitivity of gastric and colorectal cancer cells assessed with the human tumour clonogenic assay and the thymidine incorporation assayEuropean Journal Of Cancer, 1992
- Mechanisms of resistance to cisplatinPublished by Springer Nature ,1991
- Comparative chemosensitivity profiles in four human ovarian carcinoma cell lines measuring ATP bioluminescenceGynecologic Oncology, 1990
- New Colorimetric Cytotoxicity Assay for Anticancer-Drug ScreeningJNCI Journal of the National Cancer Institute, 1990
- The ATP assay is more sensitive than the succinate dehydrogenase inhibition test for predicting cell viabilityEuropean Journal of Cancer and Clinical Oncology, 1987